Evidence map›Paper›PMID 42324891›Full record

ArticlePediatric pulmonology2026

Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD-ON.

Robin Deterding, Lisa R Young, Emily M DeBoer, David Warburton, Steven Cunningham, Nicolaus Schwerk, Kevin K Brown, Václav Koucký, Jason P Weinman, Jill Simmons and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Robin DeterdingSection of Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, University of Colorado Denver, Denver, Colorado, USA.ORCID https://orcid.org/0000-0001-6890-3466
Lisa R YoungDivision of Pulmonary and Sleep Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Emily M DeBoerSection of Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, University of Colorado Denver, Denver, Colorado, USA.ORCID https://orcid.org/0000-0002-0924-9342
David WarburtonMaria Fareri Children's Hospital, New York Medical College, Boston Children's Health Physicians, Valhalla, New York, USA.
Steven CunninghamCentre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
Nicolaus SchwerkClinic for Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Kevin K BrownNational Jewish Health, Denver, Colorado, USA.
Václav KouckýMotol University Hospital and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
Jason P WeinmanThe Children's Hospital Colorado, Aurora, Colorado, USA.
Jill SimmonsVanderbilt Children's Hospital, Nashville, Tennessee, USA.
Mihaela DumistracelBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
Frauke Jantzenmainanalytics GmbH, Sulzbach (Taunus), Germany.
Martina GahlemannBoehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland.
Matthias GrieseHauner Children's Hospital, Ludwig Maximilians University, German Center for Lung Research (DZL), Munich, Germany.ORCID https://orcid.org/0000-0003-0113-912X
InPedILD‐ON trial investigators

Funding

The InPedILD and InPedILD-ON trials were supported by Boehringer Ingelheim International GmbH
6 · The paper itself

Abstract

backgroundIn the InPedILD trial, nintedanib had an acceptable safety profile in children and adolescents (aged 6-17 years) with fibrosing ILDs. The open-label extension of the InPedILD trial, InPedILD-ON, is assessing the longer-term safety of nintedanib in these patients.

methodsPatients who completed the InPedILD trial on treatment and had a transition period of ≤12 weeks entered InPedILD-ON as "rollover patients." Patients who completed the InPedILD trial and had a transition period of > 12 weeks, and new patients aged 6-17 years with fibrosing ILDs, entered InPedILD-ON as "new patients." All patients received open-label nintedanib in InPedILD-ON.

resultsForty-eight patients received nintedanib in InPedILD-ON. At baseline, mean (SD) age was 13.7 (3.2) years, and FVC was 59.4 (21.6) % predicted. At this data snapshot, median exposure to nintedanib in InPedILD-ON was 61.5 weeks. Diarrhea was the most frequent adverse event, reported at a rate of 50.4 per 100 patient-years. Seven patients discontinued nintedanib, one for each of the following reasons: adverse event (weight decrease), change of residence, burden of study procedures, pregnancy planning, clinical deterioration, other treatment option available, no reason given. Mean (SE) change in FVC % predicted at Week 52 (n = 26) was -1.0 (1.4). Mean (SE) change in SpO

conclusionThe adverse event profile of nintedanib in InPedILD-ON was generally consistent with that reported in the InPedILD trial, supporting the tolerability of nintedanib in children and adolescents with fibrosing ILDs.

Indexed as

Idiopathic Pulmonary FibrosisIndolesProtein Kinase InhibitorsAdolescentChildDiarrheaFemaleHumansMaleTreatment OutcomeIndolesnintedanibProtein Kinase Inhibitorsdisease progressiondrug side effectspediatricspulmonary fibrosisrespiratory function tests

Identifiers

PMID42324891
PMCPMC13284627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.